Author: admin

  • Thangam Debbonaire – 2016 Parliamentary Question to the Department of Health

    Thangam Debbonaire – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Thangam Debbonaire on 2016-05-26.

    To ask the Secretary of State for Health, if he will make an assessment of the potential merits of bringing forward legislative proposals to prevent the publication of books, papers and other material containing health advice which does not have a sound evidence base; and if he will make a statement.

    George Freeman

    We have no plans to make such an assessment. The Department’s policies and advice are informed by the best available evidence.

  • Tom Pursglove – 2016 Parliamentary Question to the Department of Health

    Tom Pursglove – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Tom Pursglove on 2016-05-26.

    To ask the Secretary of State for Health, pursuant to the Answer of 25 May 2016 to Question 37198, how many of the leaflets entitled Why the Government believes that voting to remain in the European Union is the best decision for the UK have been returned to his Department; and what the postage cost to the Government has been of such returns.

    Jane Ellison

    I refer the hon. Member to the Prime Minister’s response of 25 May 2016. This information is not collated centrally by the Department.

  • Nigel Mills – 2016 Parliamentary Question to the Department of Health

    Nigel Mills – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Nigel Mills on 2016-05-26.

    To ask the Secretary of State for Health, what assessment his Department has made of potential links between hand hygiene compliance levels across the NHS and rates of C. Difficile bacteraemia in 2015.

    Ben Gummer

    Tackling healthcare associated infections is complex and requires a strong patient safety system that integrates cleanliness, infection prevention and control and antibiotic use. Hand hygiene is an important component and we continuously review and enhance national measures, systems and guidance. For example hand hygiene references in The Health and Social Care Act 2008 Code of Practice for prevention and control of infections and related guidance, were strengthened when it was revised in 2015. It will also form part of forthcoming guidance on reducing Gram negative infections such as E. coli.

    Auditing of hand hygiene is a local responsibility and information on hand hygiene compliance is not collected centrally. Therefore, no national assessment has been made of the potential links between hand hygiene compliance levels and the above infections.

  • Nigel Mills – 2016 Parliamentary Question to the Department of Health

    Nigel Mills – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Nigel Mills on 2016-05-26.

    To ask the Secretary of State for Health, what assessment his Department has made of potential links between hand hygiene compliance levels across the NHS and rates of MSSA bacteraemia in 2015.

    Ben Gummer

    Tackling healthcare associated infections is complex and requires a strong patient safety system that integrates cleanliness, infection prevention and control and antibiotic use. Hand hygiene is an important component and we continuously review and enhance national measures, systems and guidance. For example hand hygiene references in The Health and Social Care Act 2008 Code of Practice for prevention and control of infections and related guidance, were strengthened when it was revised in 2015. It will also form part of forthcoming guidance on reducing Gram negative infections such as E. coli.

    Auditing of hand hygiene is a local responsibility and information on hand hygiene compliance is not collected centrally. Therefore, no national assessment has been made of the potential links between hand hygiene compliance levels and the above infections.

  • Nigel Mills – 2016 Parliamentary Question to the Department of Health

    Nigel Mills – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Nigel Mills on 2016-05-26.

    To ask the Secretary of State for Health, what plans his Department has to review and update NICE guidance to take account of emerging new technologies in electronic auditing.

    George Freeman

    Neither the Department nor the National Institute for Health and Care Excellence has any plans to do so.

  • Wendy Morton – 2016 Parliamentary Question to the Department of Health

    Wendy Morton – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Wendy Morton on 2016-05-26.

    To ask the Secretary of State for Health, how many cases of Ehlers-Danios Syndrome have been diagnosed in each of the last five years.

    George Freeman

    These data are not held centrally by the Department.

    Ehlers-Danlos Syndrome (EDS) is a complex group of heritable disorders of connective tissue with an estimated prevalence of one in 20,000. As EDS appears in a variety of forms rates of diagnosis can be underestimated.

  • Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Gwynne on 2016-05-26.

    To ask the Secretary of State for Health, whether the Parliamentary Under Secretary of State for Public Health has seen the complaint by the Nordic Cochrane Centre to the European Medicines Agency regarding maladministration at that organisation; and if he will make a statement.

    Jane Ellison

    I am aware of the document from the Nordic Cochrane Centre. Whilst the issues raised are a matter for the European Medicines Agency (EMA), we are satisfied that the EMA has adequate processes in place to manage any potential conflicts of interest of its scientific experts and to uphold the integrity and impartiality of its decision-making. There was consensus agreement amongst EU Member States on the conclusions of the recent human papilloma virus (HPV) vaccine safety review, and we have confidence in the outcome of this review.

    Aside from the EMA review, the World Health Organization’s Global Advisory Committee on Vaccine Safety advised in December 2015 that it had not found any safety issues to date that would alter its recommendation to use the vaccine. It concluded that there is no evidence that postural orthostatic tachycardia syndrome and complex regional pain syndrome are associated with HPV vaccination. Thorough reviews undertaken by the US Centre for Disease Control and Prevention and Health Canada have also concluded that available evidence does not support a link between HPV vaccine and development of serious and chronic illnesses.

  • Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Gwynne on 2016-05-26.

    To ask the Secretary of State for Health, what compliance procedures the Medicines and Healthcare Products Regulatory Agency has to ensure that its pharmacovigilance functions do not conflict with the relationships it builds with private companies when seeking business from such companies.

    George Freeman

    The requirements for the pharmacovigilance functions of the Medicines and Healthcare products Regulatory Agency (MHRA) are set out in European legislation through Directive 2010/84/EU and Regulation (EU) No 1235/2010 and in the Human Medicines Regulations 2012. MHRA is required to carry out independent audits of these pharmacovigilance functions and report to the European Commission every two years. This is in addition to routine reporting to the Commission on Human Medicines.

    The requirements on private companies in the pharmaceutical industry that hold Marketing Authorisations for medicinal products are also set out in the same legislation and the MHRA carry out inspections to ensure these companies are compliant with the requirements. The MHRA has contact with pharmaceutical companies in its day to day business as necessary to fulfil the requirements of its pharmacovigilance functions.

  • Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    Andrew Gwynne – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Andrew Gwynne on 2016-05-26.

    To ask the Secretary of State for Health, what measures are in place to support people who have had adverse reactions to vaccines administered by the NHS.

    Jane Ellison

    The Vaccine Damage Payments Scheme (VDPS) was set up under the Vaccine Damage Payments Act 1979 to provide a measure of financial help in those very rare circumstances where it is established that severe disability was caused by vaccination administered by the National Health Service.

    It is only one part of the wide range of support and help available to severely disabled people in the United Kingdom. The VDPS does not prejudice the right of the injured person to pursue a claim for compensation against the manufacturer of the vaccine.

  • Alex Cunningham – 2016 Parliamentary Question to the Department of Health

    Alex Cunningham – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Alex Cunningham on 2016-05-26.

    To ask the Secretary of State for Health, what steps his Department is taking to address barriers faced by people with ME in accessing care and support; and if he will make a statement.

    Jane Ellison

    The commissioning of services for people with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), is a local matter. To support the local NHS in shaping services for people with CFS/ME, the National Institute for Health and Care Excellence (NICE) has published a clinical guideline on the management of CFS/ME in adults and children, which set outs best practice on the care, treatment and support of people with the condition.

    Although there is no cure for CFS/ME, there are treatments that may help to ease symptoms. The NICE guideline on CFS/ME recommends treatment such as cognitive behavioral therapy and graded exercise therapy approaches, which have the clearest research evidence of benefit. However, the guideline is clear that there is no one form of treatment to suit every patient. Treatment approaches will not be appropriate for all patients and the needs and preferences of patients should be taken into account. Shared decision-making between patients and healthcare professionals should take place during diagnosis and all phases of care. Furthermore, patients should be offered information about local and national self-help groups and support groups for people with CFS/ME and their carers.

    NICE last reviewed the guidance with its stakeholders, including CFS/ME charities during 2013. The review found no update was required. The full guideline may be viewed on the NICE website at the following link:

    www.nice.org.uk/guidance/cg53

    “